{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=17",
    "query": {
      "condition": "Schizophrenia Spectrum and Other Psychotic Disorders",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1651,
    "total_pages": 166,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T07:20:20.506Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03978832",
      "title": "Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "PERSERIS",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 69,
      "start_date": "2019-06-28",
      "completion_date": "2020-05-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-07",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 1,
      "location_summary": "Garden Grove, California",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03978832"
    },
    {
      "nct_id": "NCT03671525",
      "title": "Cognitive Effects of Nimodipine in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizo Affective Disorder"
      ],
      "interventions": [
        {
          "name": "Nimodipine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-10-05",
      "completion_date": "2023-05-12",
      "has_results": false,
      "last_update_posted_date": "2023-06-23",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03671525"
    },
    {
      "nct_id": "NCT00111189",
      "title": "A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone Palmitate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 414,
      "start_date": "2005-02",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2014-06-20",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 18,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00111189"
    },
    {
      "nct_id": "NCT00884897",
      "title": "Oxytocin and Social Cognition in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Social Cognition",
        "Social Anxiety",
        "Emotional Intelligence"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2010-01",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 1,
      "location_summary": "Catonsville, Maryland",
      "locations": [
        {
          "city": "Catonsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00884897"
    },
    {
      "nct_id": "NCT00053703",
      "title": "Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine (enrollment closed in this treatment)",
          "type": "DRUG"
        },
        {
          "name": "Molindone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "8 Years to 19 Years"
      },
      "enrollment_count": 116,
      "start_date": "2002-02",
      "completion_date": "2007-05",
      "has_results": true,
      "last_update_posted_date": "2014-03-26",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 4,
      "location_summary": "Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Medford",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053703"
    },
    {
      "nct_id": "NCT00937261",
      "title": "Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 96,
      "start_date": "2009-07",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2010-10-28",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00937261"
    },
    {
      "nct_id": "NCT00167362",
      "title": "Cognitive Enhancement Therapy for Early-Stage Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Cognitive enhancement therapy (CET)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enriched supportive therapy (EST)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "51 Years",
        "sex": "ALL",
        "summary": "16 Years to 51 Years"
      },
      "enrollment_count": 67,
      "start_date": "2001-08",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-10",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167362"
    },
    {
      "nct_id": "NCT07006935",
      "title": "REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizo Affective Disorder",
        "Schizophreniform Disorders"
      ],
      "interventions": [
        {
          "name": "Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Community-Based Mental Health Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Case Western Reserve University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-08-30",
      "completion_date": "2028-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07006935"
    },
    {
      "nct_id": "NCT01123408",
      "title": "Clozapine and Olanzapine Treatment of Aggression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Clozapine",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Haloperidol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nathan Kline Institute for Psychiatric Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 110,
      "start_date": "1999-06",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2010-05-14",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 1,
      "location_summary": "Orangeburg, New York",
      "locations": [
        {
          "city": "Orangeburg",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01123408"
    },
    {
      "nct_id": "NCT00224822",
      "title": "The Effects of Aripiprazole on Patients With Metabolic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder",
        "Metabolic Syndrome X"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico VA Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2004-03",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2010-03-24",
      "last_synced_at": "2026-10-15T07:20:20.506Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00224822"
    }
  ]
}